drugset / Trial / NCT00952237
Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF
NaSingle-groupOpen-labelTreatment
Summary
We postulate that the combination of IL-2 and GM-CSF immunotherapy will efficiently mobilize autologous peripheral blood stem cells and activated immune effector cells in patients with a hematologic malignancy. These activated effector cells will improve the immune function of the graft. These hypotheses will be tested using this proposed clinical trial to mobilize autologous peripheral blood stem cells pre-transplantation.
Timeline
- Start
- 2003-01
- Primary completion
- 2011-04
- Completion
- 2011-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | aldesleukin | Protein / enzyme biologic | 300000 unknown | Subcutaneous |
| Subject | aldesleukin | Protein / enzyme biologic | 600000 unknown | Subcutaneous |
| Subject | aldesleukin | Protein / enzyme biologic | 1e+06 unknown | Subcutaneous |
| Subject | aldesleukin | Protein / enzyme biologic | 1.5e+06 unknown | Subcutaneous |
| Subject | aldesleukin | Protein / enzyme biologic | 2e+06 unknown | Subcutaneous |
| Subject | sargramostim | Protein / enzyme biologic | 7.5 ug/kg | — |
| Background | G-CSF | Unknown | 5 ug/kg | — |